wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
CNCR.28561
CNCR.28561
http://dx.doi.org/10.1002/CNCR.28561
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.
P356
Q34180815-0B823170-F2C3-48EA-947B-FA0F58DA7EE5
P356
CNCR.28561
http://dx.doi.org/10.1002/CNCR.28561